Compare Moderna, Inc. (MRNA) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs iShares Semiconductor ETF — how do they compare? Moderna, Inc. trades at $224.91 (market cap $78.65B), while iShares Semiconductor ETF trades at $559.82 (market cap $48.19B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, iShares Semiconductor ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and iShares Semiconductor ETF for 46 Days on average.
| MRNA | SOXX | |
|---|---|---|
Market Cap | $78.65B | $48.19B |
Volume | 37,373,437 | 10,257,578 |
Sector | Health | Sector/Thematic |
52-Week High | $203.46 | $655.01 |
52-Week Low | $22.36 | $268.10 |
Typical Hold Time | 59 Days | 46 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
SOXX trades at $559.40, down 4.04% over the past 24 hours amid broader semiconductor sector volatility. The ETF maintains a bullish technical signal with strong moving average support, while oscillators show neutral momentum. Recent news highlights continued AI-driven semiconductor demand with projections of market growth to $2.3 trillion by 2030, though concerns about valuation premiums and Michael Burry's expanded short positions create mixed sentiment.
The semiconductor sector faces a critical juncture with AI infrastructure demand driving earnings growth while elevated valuations present headwinds. SOXX's fundamental strength depends on continued chip industry expansion, though concentration risk and potential market rotation pose significant challenges for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
